← Back to Home

Getting Clot-Dissolving Drugs Through Stagnant Blood Flow: Magnetically Controlled Microrobots Improve Vessel Reopening in Pig Experiments

Blood clots block vessels and prevent drugs from reaching them. ETH Zurich has used magnetic hydrogel particles to stir local fluid flow, achieving preliminary results in laboratory experiments and pig renal artery models; whether they can be used safely in humans remains to be verified.

By SURL BioNews

Treating blood clots presents a difficult challenge: the more blocked a vessel becomes, the harder it is for clot-dissolving drugs to reach the clot through the bloodstream. Even when a catheter delivers drugs nearby, the final stretch may still be hindered by stagnant fluid. A research team at ETH Zurich is trying to use magnetically controlled microrobots to move fluid along this stretch, making it easier for drugs to reach the clot. So far, the team has observed effects in laboratory experiments and live pig models.

The team, led by Simone Schürle, calls these microrobots HydroBots. They consist of chains of iron oxide nanoparticles coated in a dextran hydrogel. They are elongated, approximately 8 micrometers long, and similar in scale to red blood cells. When an external device generates a rotating magnetic field, the particles tumble along the vessel wall, pushing and pulling the surrounding fluid to create local flow where flow was previously insufficient.

The key to this design is improving drug transport. According to ETH’s announcement and Singularity Hub’s account, the microrobots and clot-dissolving drugs are delivered through a catheter to a location near the clot; the drugs are not loaded inside the robots. Instead, fluid flow generated by the moving particles pushes the drugs toward the blockage. The research thus extends the treatment bottleneck from “whether the drug is potent enough” to “whether the drug can reach its site of action.”

ETH announced on November 9 that, in vessel-mimicking channels containing pig blood clots, adding microrobots allowed the drugs to dissolve clots approximately six times as fast as drugs alone. A preprint made public in March described a tenfold improvement; a closer look at the experiments shows that the nearly tenfold figure referred to the peak rate at which trypsin dissolved artificial fibrin plugs. The pig blood clot experiments separately reported a final extent of dissolution approximately five to six times that of the control group. These materials and measurement endpoints differ and cannot be combined into a single efficacy figure.

Animal experiments further tested the arteries supplying the kidneys. After creating a clot-induced blockage, the researchers compared HydroBots combined with tissue plasminogen activator (tPA) against tPA alone. According to ETH’s announcement, after 30 minutes of treatment, the area of the vascular region in which blood flow had been restored was approximately twice as large in the group receiving microrobots as in the group receiving the drug alone. This provides preliminary evidence in large animals, but it does not yet support conclusions about improved survival or organ function in patients with stroke or myocardial infarction.

Reopening vessels within a short period also does not establish long-term safety. Live Science quoted the research team as explaining that these acute pig experiments did not track how the particles subsequently broke down or assess the animals’ longer-term outcomes. Where the particles go in the body, how they are cleared, and whether they cause delayed tissue damage all require further evidence before human trials can begin.

This research has not yet completed peer review and has not been tested in humans. ETH has filed a patent application; the preprint also discloses that Schürle is a co-founder and board member of Magnebotix AG. The next key step is to determine, through longer-term animal follow-up and specific disease models, whether improvements in local blood flow can translate into organ protection, and to clarify the risks posed by the particles themselves.

References

  1. ETH Zurich
  2. Research Square
  3. Live Science
  4. Singularity Hub